(SEER) – Company Press Releases
-
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
-
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
-
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
-
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
-
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
-
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
-
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
-
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
-
Seer Reports Third Quarter 2023 Financial Results
-
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
-
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
-
Seer to Participate in Upcoming September Investor Conferences
-
Seer Reports Second Quarter 2023 Financial Results
-
Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Seer to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center
-
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
-
Seer Reports First Quarter 2023 Financial Results
-
Seer to Report First Quarter 2023 Financial Results on May 9, 2023
-
Seer to Report First Quarter 2023 Financial Results on May 9, 2023
-
Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
-
Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
-
Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook
-
Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook
-
Seer to Present at the Cowen 43rd Annual Health Care Conference
-
Seer to Present at the Cowen 43rd Annual Health Care Conference
-
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
-
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
-
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
-
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
-
DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS
-
Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist
-
Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist
-
Seer Reports Third Quarter 2022 Financial Results
-
Seer Reports Third Quarter 2022 Financial Results
-
Seer to Report Third Quarter 2022 Financial Results on November 8, 2022
-
Seer to Report Third Quarter 2022 Financial Results on November 8, 2022
-
Probius Emerges to Transform Data Acquisition for AI in Healthcare, adding John Baldoni, Chief Scientific Officer, and Juan C. Cuevas, SVP Marketing and Business Development
-
Seer to Participate in the Morgan Stanley Global Healthcare Conference
-
Seer to Participate in the Morgan Stanley Global Healthcare Conference
-
Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome
-
Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome
-
Seer Reports Second Quarter 2022 Financial Results
-
Seer Reports Second Quarter 2022 Financial Results
-
Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0
-
Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0
-
Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
-
Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
-
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
-
Seer Reports First Quarter 2022 Financial Results
Back to SEER Stock Lookup
